These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29416802)

  • 21. PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers.
    Chen L; Yuan Y; Kar S; Kanchi MM; Arora S; Kim JE; Koh PF; Yousef E; Samy RP; Shanmugam MK; Tan TZ; Shin SW; Arfuso F; Shen HM; Yang H; Goh BC; Park JI; Gaboury L; Lobie PE; Sethi G; Lim LHK; Kumar AP
    Mol Cancer Ther; 2017 Nov; 16(11):2528-2542. PubMed ID: 29021293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and diagnostic significance of annexin A2 in colorectal cancer.
    Yang T; Peng H; Wang J; Yang J; Nice EC; Xie K; Huang C
    Colorectal Dis; 2013 Jul; 15(7):e373-81. PubMed ID: 23489866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer.
    Okano M; Kumamoto K; Saito M; Onozawa H; Saito K; Abe N; Ohtake T; Takenoshita S
    Oncol Rep; 2015 Mar; 33(3):1064-70. PubMed ID: 25592491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression.
    Abdelraouf EM; Hussein RRS; Shaaban AH; El-Sherief HAM; Embaby AS; Abd El-Aleem SA
    Life Sci; 2022 Nov; 308():120967. PubMed ID: 36116530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer.
    Liu J; Shi Z; Bai Y; Liu L; Cheng K
    Cancer Manag Res; 2019; 11():4471-4480. PubMed ID: 31191009
    [No Abstract]   [Full Text] [Related]  

  • 27. Presence of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study.
    Yanai H; Yoshikawa K; Ishida M; Tsuta K; Sekimoto M; Sugie T
    PLoS One; 2021; 16(2):e0245725. PubMed ID: 33571189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological subtypes in triple negative breast cancer are associated with specific information on survival.
    Balkenhol MCA; Vreuls W; Wauters CAP; Mol SJJ; van der Laak JAWM; Bult P
    Ann Diagn Pathol; 2020 Jun; 46():151490. PubMed ID: 32179443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
    Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
    Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression in triple-negative breast cancer in relation to survival.
    Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
    Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5.
    Guzmán-Aránguez A; Olmo N; Turnay J; Lecona E; Pérez-Ramos P; López de Silanes I; Lizarbe MA
    J Cell Biochem; 2005 Jan; 94(1):178-93. PubMed ID: 15526283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
    BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
    Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
    Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the AnxA1/FPR1 autocrine axis reduces MDA-MB-231 breast cancer cell growth and aggressiveness in vitro and in vivo.
    Vecchi L; Alves Pereira Zóia M; Goss Santos T; de Oliveira Beserra A; Colaço Ramos CM; França Matias Colombo B; Paiva Maia YC; Piana de Andrade V; Teixeira Soares Mota S; Gonçalves de Araújo T; Van Petten de Vasconcelos Azevedo F; Soares FA; Oliani SM; Goulart LR
    Biochim Biophys Acta Mol Cell Res; 2018 Sep; 1865(9):1368-1382. PubMed ID: 29932988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.
    Niu Y; Yang X; Chen Y; Jin X; Xie Y; Tang Y; Li L; Liu S; Guo Y; Li X; Duan L; Wang H
    Clin Transl Oncol; 2019 Sep; 21(9):1186-1196. PubMed ID: 30694461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.
    Sheu MJ; Li CF; Lin CY; Lee SW; Lin LC; Chen TJ; Ma LJ
    Tumour Biol; 2014 Aug; 35(8):7755-63. PubMed ID: 24810927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue plasminogen activator receptor ANXA2 and its complementary regulator anti-inflammatory ANXA1 as prognostic indicators of inflammatory response in COVID-19 pathogenesis.
    Shenoy RD; Nithin Kuriakose ; Vijaykrishnaraj M ; Patil P; Jayaswamy PK; Alagundagi DB; Shetty P
    Immunobiology; 2023 Sep; 228(5):152728. PubMed ID: 37579635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs.
    Fan Y; Ding X; Wang J; Ma F; Yuan P; Li Q; Zhang P; Xu B
    Int J Biol Markers; 2015 May; 30(2):e200-7. PubMed ID: 25953090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
    Zhang Y; Bi J; Zhu H; Shi M; Zeng X
    Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.